A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Authors
Discussion
Loading...
Member takes
Implication
Randomized double-blind trial shows reduced spleen size and improved survival with ruxolitinib in myelofibrosis, highlighting clinical benefit despite early anemia and thrombocytopenia.
Key Points
- To evaluate the clinical efficacy and safety of ruxolitinib compared with placebo in patients with myelofibrosis.
- Conducted a double-blind, placebo-controlled randomized clinical trial (COMFORT-I; ClinicalTrials.gov number, NCT00952289).
- Assigned patients with myelofibrosis to receive either ruxolitinib or placebo to assess changes in spleen volume, disease-related symptoms, and survival.
- Ruxolitinib significantly reduced spleen size, improved debilitating myelofibrosis-related symptoms, and prolonged overall survival compared with placebo.
- Treatment with ruxolitinib resulted in higher rates of anemia and thrombocytopenia during the early treatment phase relative to placebo.
Cite This Study
Verstovšek et al. (2012) studied this question.